r This is the first study to demonstrate an altered circadian phase shifting response in a circadian rhythm sleep disorder.
Introduction
Delayed sleep-wake phase disorder (DSWPD) is a circadian rhythm sleep disorder in which patients experience a delay in their major sleep episode relative to desired or socially optimal timing (American Academy of Sleep Medicine, 2014) . Patients with DSWPD often have inappropriate alignment of their circadian clock with the natural 24 h light-dark cycle (Czeisler et al. 1981) , with circadian rhythms delayed by 2-6 h relative to their desired bedtime (Micic et al. 2015) . This delay is associated with increased sleep onset latency and, combined with early school or work times, often results in chronic sleep restriction and poor sleep quality, as sleep is attempted at times when the circadian clock is promoting wake. Patients with DSWPD also have high rates of depressive symptoms (Alvarez et al. 1992; Vandeputte & de Weerd, 2003; Murray et al. 2017) , and experience significant daytime dysfunction, including lower academic performance (Lack, 1986) , increased irritability and increased daytime sleepiness (Alvarez et al. 1992 ; Kripke et al. 2008) .
A potential mechanism for the development of delayed circadian timing in DSWPD patients is an abnormal response to environmental light cues. The circadian system endogenously generates rhythms that have a period near to, but not exactly 24 h and therefore environmental time cues are required to synchronize these rhythms with the external 24 h day. Light is the most powerful synchronizing agent for the human circadian clock, with light exposure in the early biological night causing a phase delay and light exposure in the late biological night a phase advance (Minors et al. 1991; Zeitzer et al. 2000; Khalsa et al. 2003; St Hilaire et al. 2012) . While the ability of the circadian system to shift its phase is essential for synchronization to the 24 h day, abnormal sensitivity to light, combined with use of artificial sources of light in the early biological night, could result in pathological misalignment. It has been proposed that patients with DSWPD may be hypersensitive to the effects of light exposure (Czeisler et al. 1981; Dagan & Eisenstein, 1999) .
The only known study that directly compared light sensitivity in DSWPD (then referred to as Delayed Sleep Phase Syndrome; DSPS) to a healthy control group found that patients exhibited a 15% increase in melatonin suppression during 2 h of 1000 lux (cool-white fluorescent lights), compared to controls (Aoki et al. 2001) . In addition, greater melatonin suppression in response to 1.5 h of 500 lux blue light (fluorescent with blue filter) has recently been associated with later circadian phase in a subclinical group of young adults complaining of a delayed sleep schedule (Moderie et al. 2017) , suggesting greater light sensitivity may play a causal role in the development of persistent delays in circadian phase.
Although a moderate increase in the suppression of melatonin to light in DSWPD has been demonstrated previously, it has not yet been determined whether DSWPD patients exhibit an increased circadian phase resetting response to light relative to healthy controls. Additionally, sensitivity to normal room-light levels has not been examined in DSWPD patients. To address these issues, we studied the phase shifting response to a 6.5 h normal room light exposure (ß150 lux at eye level) in DSWPD patients and healthy controls. Given that DSWPD patients exhibit delayed circadian rhythms, we specifically investigated sensitivity in the delay region of the phase response curve by assessing the effect of light in the early biological night. In addition to being a normally occurring indoor lighting level (Scheuermaier et al. 2010) with known effects on melatonin suppression (Gooley et al. 2011) , 150 lux was chosen due to its position in the active region of the dose-response curve to light (far below saturating light levels) during this circadian time (Zeitzer et al. 2000) . We hypothesized that DSWPD patients would exhibit a greater phase delay and greater melatonin suppression in response to night-time light exposure, compared to healthy controls.
Methods

Ethical approval
The current study was approved by the Monash University Human Research Ethics Committee and participants gave written informed consent prior to participation (Project No. 6027 ). This study was in line with the standards set by the Declaration of Helsinki (revision no. 7), except for registration in a database.
Participants
Participants were recruited from the community via posters, online, radio and train advertisements. A total of 24 male participants completed the study: 12 patients with diagnosed DSWPD (aged 21.3 ± 3.0 years) and 12 healthy controls (aged 22.5 ± 3.1 years). Previous research has suggested sex differences in sensitivity of the circadian system to light in both animals and humans (Davis et al. 1983; Monteleone et al. 1995; Cain et al. 2010) . Therefore, only male participants were selected to reduce variability in light sensitivity within groups due to sex.
Phase 1: preliminary screening and consent. Participants were selected through three extensive screening phases (see Fig. 1 for the participant flowchart). In Phase 1, participants completed a range of online and over-the-phone questions to assess preliminary eligibility for the study. This included determining whether DSWPD patients exhibited sleep-wake behaviour consistent with a diagnosis, and that healthy controls demonstrated a healthy sleep-wake cycle. Participants were deemed eligible at this stage if: they had a BMI within the normal range of 18-30 kg m −2 , they were Caucasian, they were fluent in English (first language or equivalent), they had no medical conditions or psychological/psychiatric history that might influence sleep or circadian rhythms, they were not on any medication that would influence sleep or circadian rhythms, they were a non-smoker, daily caffeine consumptions was <300 mg, weekly alcohol consumption was <14 standard drinks, and they had not undertaken any transmeridian travel (>2 time zones) or participated in any shift work in the past 3 months. Healthy control participants had to have a self-reported sleep onset occurring between 22.00 and 00.00 h, had a sleep length of 7-9 h, did not regularly undertake naps more than once a week, and had no sleep complaints or sleep pathology. DSWPD patients were required to have sleep onset time occurring after 01.00 h, a desire to sleep earlier than their current habitual bedtime (but not earlier than 22.00 h), an inability to fall asleep at their desired bedtime and no sleep pathology other than DSWPD. Participants were additionally excluded if their Beck Depression Inventory II (BDI-II; Beck et al. 1996) score was above 13 for healthy controls to ensure their healthy control status, or above 18 for DSWPD patients to allow for mild depression symptoms, a common co-morbidity of DSWPD (Alvarez et al. 1992; Vandeputte & de Weerd, 2003; Murray et al. 2017) . Additional questionnaires completed by participants used for describing the sample included the Morning-Eveningness Questionnaire (MEQ; Horne &Östberg, 1976) ; Pittsburgh Sleep Quality Index (PSQI; Buysse et al. 1989) ; Insomnia Severity Index (ISI; Bastien et al. 2001) ; Depression, Anxiety and Stress Scale (DASS-21; Lovibond & Lovibond, 1995; Henry & Crawford, 2005) ; and the General Anxiety Disorder 7-item scale (GAD-7; Spitzer et al. 2006) . Medicine, 2014) , and a lack of any diagnoses in healthy controls. DSWPD diagnosis criteria A-C and E from the ICSD-3 were confirmed by the sleep physician and criterion D (sleep log and actigraphy for at least 7 days demonstrating a delay in the timing of the habitual sleep period) was measured and confirmed by researchers prior to participation. Participants also underwent the Structured Clinical Interview for DSM-5 (SCID-5) to assess any personal or familial history of psychological or psychiatric disorders. This interview was conducted by a provisional psychologist under the supervision of a fully registered psychologist. Healthy control participants were deemed ineligible if they had any personal or familial history of any Axis-1 disorders. DSWPD patients were excluded for any personal history of Axis-1 disorders or any familial history which could result in increased risk associated with the sleep deprivation protocol (e.g. psychosis, bipolar disorder).
Phase 3: at-home dim light melatonin onset measurement. Prior to admission to the study, participants underwent an at-home assessment of dim light melatonin onset (DLMO) to confirm normal circadian timing in control participants, and a circadian delay in DSWPD patients. Participants were seated in a dimly lit room (<5 lux, measured at eye level, standing and seated, using a calibrated photometer) and were instructed to collect hourly saliva samples using salivettes (Sarstedt, Nümbrecht, Germany) from 5 h prior to their habitual bedtime until 2 h after (a total of 7 samples). A light sensor (Hobo, Onset, Bourne, MA, USA) was pinned to each participant's clothing to ensure compliance to the lighting conditions after researchers left the premises. Participants were instructed to avoid posture change, movement, food, and drink from 30 min prior to collection of each saliva sample. Participants were also asked to refrain from caffeine, alcohol and mouthwash on the day of collection. Healthy controls were deemed eligible for further study if they had a DLMO time of earlier than 22.00 h and a normal phase relationship (i.e. DLMO had to occur 1-3 h before habitual bedtime). DSWPD patients were deemed eligible for further study if their DLMO time was later than 23.00 h, and they were classified as having 'circadian DSWPD' (Murray et al. 2017) , defined as having a DLMO within 30 min before desired bedtime or after desired bedtime (Murray et al. J Physiol 596.24 2017). For example, if desired bedtime was midnight, DLMO was required to be 23.30 h or later to be considered delayed.
In-home sleep-wake monitoring. During in-home DLMO assessment, participants were provided with a wrist-worn device (Actiwatch Spectrum Plus, Philips Respironics, Bend, OR, USA) to record activity and light levels until admission to the in-lab protocol. Participants also completed a daily sleep diary to confirm bed and wake times. Participants were required to maintain a sleep-wake cycle consistent with the inclusion characteristics of their group (i.e. DSWPD participants needed to have an average bedtime past 01.00 h, and healthy controls needed to sleep on average 7-9 h starting between 22.00 and 00.00 h), to be admitted to the in-lab protocol. Participant characteristics are presented in Table 1 .
In-laboratory protocol
Approximately 2 weeks after the at-home DLMO collection (mean = 13.5 days, SD = 4.7 days, range = 7-24 days), participants completed a 6-day stay in a completely time-cue-free (no windows, watches, TV, internet, phone or other indicators of time of day) and temperature-regulated environment (see Fig. 2 for a representative raster plot). Participants were required to abstain from all caffeine, alcohol and medication Data are presented as mean and SD. Times are given as hours and minutes. Average bedtime was determined using the pre-lab actigraphy. Dim light melatonin onset (DLMO) was measured using a 4 pg/ml cutoff (Carskadon et al. 1998) . Phase angle is the time difference (h) between DLMO and actual bedtime (not desired bedtime). DASS, Depression, Anxiety and Stress Scale.
for at least a week prior to the study, and were self-reported to be free from shift work, nicotine, prescription medication and illicit drugs for at least 3 months on the day of admission. Urine toxicology screening was performed upon admission to confirm no recent use of illicit drugs (amphetamines, THC, cocaine, opiates and phencyclidine).
A constant room temperature of ß22-23°C was maintained across the 6 day protocol. Day 1 of the study was a baseline day where saliva samples were collected, beginning from 5 h prior up until the participants' habitual bedtime, as assessed through sleep diaries and actigraphy.
Following the baseline night, participants were given an 8 h sleep opportunity starting at their habitual bedtime. Upon awakening, they commenced a 27 h constant routine protocol (CR1). Participants were kept awake in a semi-recumbent posture in dim light (<3 lux) and fed room-temperature identical isocaloric snacks consisting of a sandwich quarter, 30 ml of juice and 80 ml of water every hour for the full 27 h CR1 period. Saliva samples for measurement of melatonin were taken hourly throughout the protocol, immediately prior to the small snack. Participants completed toilet opportunities using a bedpan or urinal to minimize postural changes. At the conclusion of CR1, participants were given an 8 h sleep opportunity, before waking to a 16 h day during which a 6.5 h light exposure was delivered. Melatonin profiles from CR1 were evaluated and two DSWPD patients, and one healthy control were excluded due to failing to meet the DLMO and sleep timing eligibility criteria for their respective groups. The final eligible participant sample was 21 male participants: 10 DSWPD patients (aged 22.4 ± 3.3 years) and 11 healthy controls (aged 22.4 ± 2.4 years).
The 6.5 h light exposure was delivered beginning at each individual participant's pre-lab DLMO time, timed to occur in the delay region of the human phase response curve (PRC) to light from Khalsa et al. (2003) . Preceding and following the 6.5 h light exposure, participants remained in lighting of <3 lux. Static pupil size was measured before, during and after this 6.5 h light exposure. Participants primarily remained seated, but were permitted to stand for bathroom breaks. After the light exposure day, participants were given another J Physiol 596.24 8 h sleep opportunity prior to completing the second CR (CR2), which was identical to the first. After CR2, participants were given an extended recovery sleep of 10 h, then discharged on day 6 of the study protocol.
Lighting. Ambient lighting was generated using fluorescent lamps (Philips, Eindhoven, The Netherlands) and neutral density filters (Lee, Andover, UK), which delivered broad spectrum lighting with a correlated colour temperature of ß4029 K and spectral peak of 544 nm (MK350N spectrometer, UPRTek, Zhunan, Taiwan). Lighting was measured approximately every 8 h throughout the CRs and approximately every hour from angle of gaze during the light exposure, to ensure the stability of lighting within and between participants (Tektronix J17 Luma Colour; Beaverton, OR, USA). During periods of <3 lux, measurements taken at a height of 1.2 m on a vertical plane were approximately 3.27 lux throughout the suite and measurements taken on the horizontal plane were approximately 1.44 lux.
During the light exposure, participants were seated in front of a white wall to reduce variation in the reflection of light and therefore reduce the effects of movement on retinal light exposure. Participants were required to maintain a fixed gaze for 10 min intervals towards a point in front of them that was measured to reflect ß150 lux at angle of gaze, alternating with 10 min intervals of free gaze. During the 150 lux lighting condition, measurements taken at a height of 1.2 m on a vertical plane averaged 203 lux throughout the suite, and measurements taken on the horizontal plane averaged 91 lux. Measurements at the angle of gaze averaged 150 lux (SD = 2.66 lux). Effective illuminances for human photopigments (Lucas et al. 2014) Salivary melatonin assays. Saliva samples were taken hourly throughout the in-lab study. Participants were required to maintain a constant posture and to refrain from eating and drinking for 30 min prior to each saliva sample. Samples were frozen at −80°C, before being shipped to the Adelaide University Research Assay Facility. The samples were analysed by double antibody radioimmunoassay, using standards and reagents supplied by Buhlmann Laboratories (RKDSM-2, Buhlmann Laboratories AG, Schönenbuch, Switzerland). This assay is based on the Voultsios et al. (1997) G280 anti-melatonin antibody and 2-[ 125 I]iodomelatonin as the radioligand and follows the protocol provided by Buhlmann. The sensitivity of the assay was 4.3 pM. Saliva samples were assayed in duplicate (200 μl per duplicate). The intra-assay coefficient of variation of the at-home sample assays was 6.5%. The interassay coefficient of variation of the low concentration quality control was 13.2%, and the interassay coefficient of variation of the high concentration quality control was 8.0%. The intra-assay coefficient of variation of the in-lab sample assays was 6.7%. The interassay coefficient of variation of the low concentration quality control was 7.6%, and the interassay coefficient of variation of the high concentration quality control was 8.6%.
Pupillometry. Static pupil size was measured during and after the light exposure using an infrared pupilometer (Neuroptics PLR-2000; Irvine, CA, USA). Measurements were taken at 10 min before lights on, 1 min after lights on, and then hourly for the first 3 h of the light exposure. Following the light exposure, measurements were taken at 30 min intervals for 2 h, with a final measurement 4 h after lights off. Measurements were ß30 s in duration, and the average pupil size during each measurement was calculated after excluding any missing data due to eye blinks. Due to device malfunction, data were not available for three healthy control participants.
Statistics
Melatonin phase, melatonin amplitude, phase shift and relative phase shift. Melatonin phase shift was calculated as the difference in the timing of salivary DLMO between CR1 and CR2 (i.e. before and after the light exposure). Salivary DLMO was defined using a linear interpolation with a threshold of 25% of the peak melatonin concentration from a three-harmonic least-squares fit to the data. Salivary DLMOff was computed with the same threshold for the descending portion of the curve, and timing of melatonin midpoint was calculated as the average of DLMO and DLMOff times. Melatonin amplitude for both CR1 and CR2 was defined as the difference between the average and peak melatonin concentration from the above three-harmonic least-squares fit.
As described above, pre-lab DLMO timing was used as our estimate for what the participant's DLMO timing would be during CR1, with lights-on targeted to occur at CR1 DLMO time. However, due to high intraindividual variability within the DSWPD group (see Fig. 3 ), there was significant spread in the timing of light relative to CR1 DLMO (range was from 95 min before to 122 min after DLMO), meaning light stimuli frequently missed the intended timing (in 5 DSWPD patients and 1 healthy control it was more than 60 min off target). Different individuals therefore received light at different points on the PRC, hindering any direct comparisons of raw phase shifts between individuals or groups.
To adjust for wide variability in the circadian timing of light exposure, we compared the observed phase shift for each individual to the phase shift predicted by the PRC in Khalsa et al. (2003) , who used similar light exposure procedures and light sources (both brand and colour temperature). The relative phase shift (i.e. fraction of the predicted phase shift) was computed for each individual, providing an estimate of that individual's relative sensitivity to light. To derive the relative phase shift, we first computed a predicted phase shift, using the melatonin midpoint, from the fitted curve in Khalsa et al. (2003) . Since our light level was lower than the level used by Khalsa et al. (2003) (ß150 lux vs. ß10,000 lux), we divided the predicted phase shift by the ratio of the dose-response curve values for 150 lux vs. 10,000 lux found by Zeitzer et al. (2000) , who used 6.5 h light pulses and similar lights (both brand and colour temperature) to induce circadian phase shifting. The ratio computed was 1.61 (i.e. 10,000 lux is 1.61 times more effective than 150 lux in shifting circadian phase for the same duration light pulse). Finally, the relative phase shift was computed by dividing an individual's observed phase shift by the predicted phase shift. A value of 1 represents the average expected response from these previous studies in healthy young adults.
Melatonin suppression. The area under the curve (AUC) was calculated using the trapezoidal method for the light exposure period, and the corresponding CR1 circadian time. AUC suppression for the light exposure compared to the CR1 dark control was then calculated by determining the percentage reduction in melatonin concentration between the AUC of CR1 and the AUC of the 6.5 h light exposure.
Analyses. Group differences in the mean relative phase shift between DSWPD patients and healthy controls were analysed using an independent samples t test. Differences in melatonin suppression levels between groups over the 6.5 h light exposure were analysed using an independent samples t test. To investigate the relationship between an individual's light sensitivity (relative phase shift) and his circadian timing (melatonin midpoint), we used a linear mixed-effects model to predict melatonin midpoint. The model assumed fixed effects for group (nominal variable) and relative phase shift (continuous variable), and random effects for participants to account for individual differences. An interaction of group with relative phase shift was tested for significance.
Pupil size data were analysed using a linear mixed-effects model. The model assumed fixed effects for group (nominal variable) and time point (nominal variable), an interaction of group with time point, and random effects for participants to account for individual differences, treating the DSWPD pre-light as the reference. Time points that were 60 min or longer after lights off were grouped, because no temporal dynamics were observed in either group beyond this point.
Results
Relative phase shift
To assess the difference in overall light sensitivity between groups, the average relative phase shift was calculated for each group (n = 21, shown in Fig. 4 ) and compared using an independent samples t test. DSWPD patients had a significantly higher relative phase shift than the healthy controls (1.21 ± 0.28 vs. 0.92 ± 0.18, P = 0.02, Cohen's d = 1.02), indicating significantly greater sensitivity to light. DSWPD patients showed 31.5% greater relative phase-shift compared to healthy controls.
A linear mixed-effects model analysis was used to evaluate the ability to predict melatonin midpoint from relative phase shift (a measure of light sensitivity) and whether this was different between groups (see Fig. 5 ). The estimated effect of relative phase shift was 1.66 h (P = 0.02, 95% CI: 0.28-3.04 h), meaning that for an increase of 0.1 in the relative phase shift (i.e. 10% of the predicted response), there was a 0.16 h delay in melatonin midpoint. No significant interaction of relative phase shift with group was detected, meaning we assume a fixed slope in both groups. The effect of group was 4.10 h (P < 10 −8 , 95% CI: 3.28-4.91 h), meaning that for the same relative phase shift (i.e. light sensitivity), a DSWPD participant was on average 4.10 h later in his melatonin midpoint than a healthy control participant. Figure 6 shows the AUC suppression for each participant (n = 21) during the 6.5 h light exposure. The DSWPD patients (mean = 77.03, SD = 21.48) showed 12.6% more melatonin suppression on average than the healthy J Physiol 596.24 control participants (mean = 64.40, SD = 21.27), but this difference was not statistically significant (P = 0.19, Cohen's d = 0.59, independent samples t test). Based on the dose-response curve of Zeitzer et al. (2000) in healthy participants, the expected suppression level at 150 lux is approximately 75%. A larger proportion of DSWPD patients demonstrated suppression above this level (60%) than healthy controls (18%), but this difference in proportion did not reach statistical significance (P = 0.08, OR: 0.15, 95% CI: 0.02-1.08, Fisher's exact test).
Melatonin suppression
Figure 4. Larger circadian phase shifting is observed in DSWPD group than control group
A, individual datapoints for phase shift (y-axis) vs. circadian timing of the light exposure based on DLMO (x-axis), showing Control (blue circles) and DSWPD (red triangles). The black curve shows the predicted phase shift, using the phase response curve (PRC) from Khalsa et al. (2003) , rescaled by a factor of 1.61 to match our lower brightness stimulus (150 vs. 9500 lux), based on the human dose response curve to light published in Zeitzer et al. (2000) . Plotting uses the convention from Khalsa et al. (2003) , where circadian time of 22.00 h represents the melatonin midpoint. B, relative phase shifts are plotted for each individual, defined as the actual phase shift divided by the predicted phase shift from panel A. A significant group difference is found between DSWPD and controls (P < 0.05). In both panels, dark grey shading represents within 15% of predicted and light grey shading represents within 30% of predicted. [Colour figure can be viewed at wileyonlinelibrary.com]
Melatonin amplitude
Independent samples t tests were used to assess if there were any intra-and interindividual and group differences in melatonin amplitude between CR1 and CR2. There was no significant difference in average melatonin amplitude between healthy controls (mean = 10.09, SD = 3.31) and DSWPD patients (mean = 10.67, SD = 4.69) during CR1 (P = 0.75, Cohen's d = 0.14), or healthy controls (mean = 8.73, SD = 2.88) and DSWPD patients (mean = 10.40, SD = 4.91) during CR2 (P = 0.35, Cohen's d = 0.41). There were also no significant differences between CR1 and CR2 within healthy control participants (P = 0.07, Cohen's d = 0.44) or CR1 and CR2 within DSWPD patients (P = 0.56, Cohen's d = 0.06). 
Pupil size
Static pupil sizes were compared between groups (n = 19, 10 DSWPD patients, 9 healthy controls) and across time points using a linear mixed-effects model. As shown in Fig. 7 , there was no significant effect of group in the reference level (i.e. pre-light). There were significant effects of time compared to the reference level (i.e. pre-light) at Light on + 60 min (−0.95 mm, 95% CI: −1.61 to −0.28 mm, P < 0.01), Light on + 120 min (−1.04 mm, 95% CI: −1.71 to −0.38 mm, P < 0.01), Light on + 180 min (−0.89 mm, 95% CI: −1.55 to −0.23 mm, P < 0.01), and Light off + 30 min (−0.71 mm, 95% CI: −1.37 to −0.04 mm, P < 0.05), indicating smaller pupil diameter for both groups during and shortly after the light exposure. There was additionally a significant interaction effect of group with time at Light off + 60 min onwards (0.82 mm, 95% CI: 0.03-1.61 mm, P <0.05), indicating that after the light exposure, DSWPD patients had significantly smaller pupil diameter relative to healthy controls.
Discussion
This was the first study to directly examine phase shifting responses to light in DSWPD. DSWPD patients showed a 31.5% larger phase-shifting response to the moderate intensity evening light exposure (ß150 lux) compared to healthy controls, demonstrating increased sensitivity of the circadian system to light. Notably, this was shown using a normal indoor light level, typically experienced during the night. This finding highlights the importance of light sensitivity in disease vulnerability.
We examined differences in the phase shifting response between DSWPD patients and healthy controls to evening light exposure. Due to high interindividual variability in the circadian timing of light exposure, we applied a novel PRC-based method to correct for individual differences in timing of the light stimulus. We found that those with DSWPD had a greater phase shifting response than controls, demonstrating increased sensitivity to phase-delaying light. This increased sensitivity creates a physiological vulnerability to light at night causing delays (e.g. artificial light sources). This physiological mechanism is consistent with changes in sleep-wake behaviour alone failing to alleviate symptoms in DSWPD; over 90% of DSWPD patients regress to pre-treatment symptoms within 1 year of ceasing treatments to correct circadian phase, with over a quarter relapsing within 1 week (Dagan et al. 2009 ). Such high treatment failure rates demonstrate that aligning sleep-wake behaviour to an earlier time has only transient benefits in the vast majority of patients. Without addressing the increased phase-delaying response to evening light, regression to abnormally late timing is likely to recur. A focus on blocking or avoiding even moderate light levels may be of particular importance in treatment efficacy.
Within both healthy control and DSWPD patient groups, we found that later melatonin timing was associated with larger phase shifts (i.e. increased light sensitivity). This indicates that increased sensitivity predicts later circadian timing, even in the absence of sleep pathology. Light sensitivity may therefore be an important determinant factor for an individual's chronotype in addition to other circadian or sleep homeostatic factors (Phillips et al. 2010; Van der Meijden et al. 2016) . The DSWPD phenotype may be a pathological manifestation of the relationship between light sensitivity and chronotype.
If light sensitivity alone were the mechanism behind DSWPD development, we would expect minimal overlap in light sensitivity between groups. Instead, however, we observed DSWPD patients with relatively early circadian timing who had similar light sensitivity to healthy controls with relatively late circadian timing. Moreover, we observed healthy controls with typical circadian timing and high light sensitivity, as well as DSWPD patients with abnormally late timing and low light sensitivity. These observations indicate that factors other than light sensitivity must play an important role in the development of delayed circadian phase and DSWPD. The DSWPD patients have a later circadian phase by ß4 h than would be predicted given their light sensitivity, implying that behavioural light exposure patterns (e.g. self-selected exposure to artificial sources of light) also play an important role in the aetiology of DSWPD. This is supported by studies demonstrating increased night-time light exposure in DSWPD patients (Auger et al. 2011; Van der Maren et al. 2018) , as well as modelling results that show increased use of artificial light sources J Physiol 596.24 amplifies individual differences in circadian and sleep timing (Skeldon et al. 2017; Swaminathan et al. 2017) . Therefore, it is likely that delayed timing in DSWPD is a result of both physiological and behavioural differences.
We found a trend towards greater melatonin suppression in DSWPD patients compared to healthy controls, with comparable difference in suppression (12.6%) to the 15% difference between DSWPD patients and controls reported by Aoki et al. (2001) . Greater melatonin suppression may contribute to a decreased signal for sleep and increased alertness, contributing to the inability to initiate sleep at a desired time. Melatonin may also work to antagonize phase shifting directly (Hunt et al. 2001) or produce advances that counteract the delaying response to light (Wright et al. 1986; Dahlitz et al. 1991) . Thus, a greater melatonin suppression response could plausibly contribute to the greater phase shifting response in DSWPD.
It has been suggested that patients with DSWPD may be sleeping through the advance portion of their PRC and therefore not receiving sufficient morning light, perpetuating delays in circadian phase (Ozaki et al. 1996) . While this may occur during times when patients are trying to catch up on lost sleep (e.g. on weekends), it does not appear to explain the circadian delays seen in our patient sample. Given the strict criteria in this study for DSWPD patients to have normal phase angles and regular average bedtimes, participants typically woke ß10 h (range = 7.5-12 h) after melatonin onset, during the advance region of their PRC and therefore were likely to receive comparable light exposure during this time to healthy controls. Hypersensitivity to evening light is likely to be a contributor to DSWPD, being perpetuated by behavioural factors such as unstable and delayed sleep schedules and night-time light exposure. This would be consistent with the recent finding that light patterns in individuals with irregular, delayed sleep patterns predict differences in circadian timing .
We found that DSWPD patients had reduced pupil size following the experimental light exposure, relative to healthy controls. At no point during or after exposure did DSWPD patients have larger pupil size. This indicates that our observed differences in phase shifting response between groups were not simply due to more light reaching the retina in DSWPD patients. It has been shown that a larger pupil diameter during light exposure is related to higher melatonin suppression (Higuchi et al. 2008) ; therefore, based on pupil size alone, our healthy control participants would be expected to have larger phase shifts than DSWPD patients. The larger phase shifts seen in our DSWPD patients are likely due to physiological differences at the level of the retina, retinohypothalamic tract, or the suprachiasmatic nucleus (SCN). Sustained pupil constriction is driven by the activation of melanopsin-containing intrinsically photosensitive retinal ganglion cells (ipRGCs; Gooley et al. 2012; Adhikari et al. 2015) . Differences in ipRGC function (as measured by sustained pupil responses) should relate to the ability of light to impact the circadian clock. Supporting this, it was found that greater sustained pupil constriction associated with later preferred and habitual sleep timing (Van der Meijden et al. 2016) . Additionally, a single nucleotide polymorphism on the melanopsin gene (OPN4) was shown to relate to pupil size during light exposure (Higuchi et al. 2013) . The potentially sustained constriction seen in our DSWPD patients may indicate an underlying increase in light signalling to the SCN after the light stimulus has ended, and therefore may be one of the physiological mechanisms underlying the greater phase shifting response seen in this group.
There are two notable limitations to our study. First, this study only examined differences in the delay region of the PRC. The assumption used for our analysis is that the shape of the PRC is locally similar in the delay region between DSWPD and healthy controls, differing primarily in amplitude between the groups. This assumption does not preclude potential differences in other aspects of the PRC. For example, the advance region of the PRC (occurring in the morning) could be blunted, or the delay region could be different in width in DSWPD compared to healthy controls. Full PRCs comparing DSWPD and healthy controls would be needed to resolve this question. Second, given potential differences between men and women in light sensitivity (Monteleone et al. 1995) , our study only included male participants. Further study will be needed in women with DSWPD to determine whether alternative mechanisms underlie this disorder in women.
Our findings have important implications for the treatment and mitigation of DSWPD. Current treatments typically focus on restoring normal sleep-wake timing. These treatments require a high level of adherence and consistency from patients. Furthermore, these treatments fail to address any underlying physiological mechanisms that may be perpetuating circadian delays. It was recently demonstrated that as many as 43% of patients diagnosed with DSWPD do not exhibit a delay in circadian phase, indicating that the cause of their sleep disturbance is not circadian in nature (Murray et al. 2017) . Despite our selection criteria requiring a late DLMO time, we still found a wide range in levels of circadian light sensitivity within our DSWPD group. This finding indicates that both circadian timing and circadian light sensitivity provide independently useful clinical information. For example, some patients may exhibit late timing in the absence of increased sensitivity, and therefore may benefit from a Cognitive Behavioral Therapy for Insomnia (CBT-I) intervention. Others may present with both late timing and increased sensitivity and therefore may benefit from strict light-dark scheduling with 'light hygiene' practices (avoidance of light at night, use of filters on devices, etc.).
It is therefore essential that clinically viable measures of these two related but distinct physiological characteristics (circadian timing and light sensitivity) are developed to inform individualized treatment practices. Information derived from such measures could also be input to mathematical models of the circadian system that predict circadian and sleep-wake timing in terms of underlying physiology (Phillips et al. 2010) , enabling improved predictions of individual-level responses to therapeutic interventions.
Although various studies have suggested altered sensitivity to light may play a role in the aetiology of circadian rhythm sleep disorders, this study was the first to examine differences in the phase shifting response to light between a patient group and healthy controls. Our findings will inform the development of mechanism-based interventions for DSWPD, which could include targeting light sensitivity or tailoring behavioural modifications to reduce or increase light exposure at appropriate times of day. 
